MDT

From a fundamental perspective, Medtronic demonstrates robust growth metrics, with a year-over-year revenue growth of 842.9% and a quarter-over-quarter revenue growth of 9.9%. The company reported earnings per share (EPS) of $3.73, with a notable EPS growth of 17.1% quarter-over-quarter. Despite these impressive figures, the stock's price-to-earnings (P/E) ratio stands at 21.3, which is relatively high compared to the forward P/E of 13.3, suggesting that the stock may be fairly valued given its growth trajectory. Analysts have a consensus rating of BUY, with a target price of $98.00, indicating that the stock could be undervalued by approximately 12.2% based on recent revenue performance.

Earnings for Medtronic are not scheduled within the next 30 days, with the last report dated April 30, 2026. Recent news highlights the company's completion of a $550 million acquisition of Scientia Vascular, which could enhance its product offerings and market reach. However, investors should keep an eye on the gross margin, which is exceptionally high at 6501.8%, and the operating margin at 1778.4%, as any indications of margin compression could signal a shift in profitability. As Medtronic continues to navigate its growth strategy, monitoring upcoming developments and the impact of acquisitions on its financial health will be crucial.